The prognostic value of the controlling nutritional status score in patients with myelodysplastic syndrome

Purpose To evaluate the prognostic value of the controlling nutritional status score (CONUT) in patients with myelodysplastic syndrome (MDS). Methods The clinical data of 81 newly diagnosed MDS patients treated with decitabine in the hematology ward of our hospital from October 2009 to September 2020 were analyzed retrospectively. According to the ROC curve of overall survival (OS), the best cutoff value of CONUT was obtained. MDS patients were divided into high CONUT score group and low CONUT score group according to the best cut-off value, and their clinical characteristics and survival were analyzed. Results Among the 81 patients with MDS, there were 32 cases in the high CONUT score group and 49 cases in low CONUT score group. Compared with the low CONUT group, the high CONUT group had lower levels of hemoglobin, lymphocyte count, albumin, and total cholesterol (P = 0.037, <0.001, 0.009, <0.001). The median OS of low and high CONUT groups were 17.2 and 11.0 months (P = 0.017). According to the results of univariate and multivariate survival analysis of OS, thrombocytopenia, high CONUT score, and medium and high risk IPSS-R score were independent prognostic factors. Conclusion High CONUT score is associated with low hemoglobin in patients with MDS. High CONUT score indicates poor OS and it is an independent prognostic factor in patients with MDS.

Automated summary

The prognostic value of the controlling nutritional status score (CONUT) in patients with myelodysplastic syndrome (MDS) was evaluated. The results showed that high CONUT score was significantly associated with low hemoglobin levels and indicated poor overall survival. Thrombocytopenia, high CONUT score, and medium and high risk IPSS-R score were identified as independent prognostic factors in MDS patients.